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Duchenne muscular dystrophy (DMD) is a severe muscle wasting
disease arising from defects in the dystrophin gene, typically
nonsense or frameshift mutations, that preclude the synthesis of a
functional protein. A milder, allelic version of the disease, Becker
muscular dystrophy, generally arises from in-frame deletions that
allow synthesis of a shorter but still semifunctional protein. Ther-
apies to introduce functional dystrophin into dystrophic tissue
through either cell or gene replacement have not been successful
to date. We report an alternative approach where 2*-O-methyl
antisense oligoribonucleotides have been used to modify process-
ing of the dystrophin pre-mRNA in the mdx mouse model of DMD.
By targeting 2*-O-methyl antisense oligoribonucleotides to block
motifs involved in normal dystrophin pre-mRNA splicing, we in-
duced excision of exon 23, and the mdx nonsense mutation,
without disrupting the reading frame. Exon 23 skipping was first
optimized in vitro in transfected H-2Kb-tsA58 mdx myoblasts and
then induced in vivo. Immunohistochemical staining demonstrated
the synthesis and correct subsarcolemmal localization of dystro-
phin and g-sarcoglycan in the mdx mouse after intramuscular
delivery of antisense oligoribonucleotide:liposome complexes.
This approach should reduce the severity of DMD by allowing a
dystrophic gene transcript to be modified, such that it can be
translated into a Becker-dystrophin-like protein.
Duchenne muscular dystrophy (DMD), an X-linked recessivedisorder, is the most common form of muscular dystrophy,
occurring at a frequency of about 1 in every 3,500 live male births
(1). Arising from the absence of a functional dystrophin protein,
the disease is characterized by severe, progressive muscle wasting
and weakness that becomes clinically evident between the ages
of 3 and 5 years. Affected boys have difficulty rising from the
floor and eventually become restricted to a wheelchair by the age
of 12 years, with 90% dying before their 20th birthday because
of cardiac and respiratory complications (2). A third of DMD
cases are the result of a de novo mutation in the dystrophin gene
(3, 4), and consequently this disease can never be eradicated
through genetic screening and counseling, placing additional
emphasis on the need to develop a treatment for this disorder.
The vast majority of DMD mutations disrupt the dystrophin
mRNA reading frame or introduce a stop codon that prema-
turely ends protein translation (5). In the less severe allelic form
of the disease, Becker muscular dystrophy (BMD), dystrophin
gene mutations are usually such that the mRNA reading frame
is maintained. Thus in BMD patients, some functional gene
product, albeit of reduced quantity andyor quality, is synthesized
that contributes to the milder phenotype (6).
The mdx mouse (7) is one animal model that has been used to
evaluate a variety of therapies for DMD, including myoblast
transfer, dystrophin cDNA replacement through viral and plas-
mid vectors, and up-regulation of a homologous protein such as
utrophin (8, 9). The genetic lesion in the mdx dystrophin gene is
a nonsense mutation at base 3185 of the mRNA that causes
premature termination of translation within exon 23. This non-
sense mutation should preclude synthesis of a functional protein,
yet rare dystrophin-positive (revertant) fibers have been ob-
served after immunohistochemical staining of mdx dystrophic
muscle (10, 11). Revertant fibers have also been observed in
many DMD patients (12) and the canine model of DMD (13).
Several RNA and protein studies have suggested that a frame-
restoring exon-skipping mechanism is the most likely cause of
these naturally occurring dystrophin-positive fibers (14, 15).
Although the number of revertant fibers increases with age, their
frequency is thought by some to be too low to be of any clinical
benefit (16). Other studies have shown that some DMD boys
with very low levels of dystrophin, as demonstrated by immu-
nostaining, lost mobility some 2 years later than those with no
detectable dystrophin (17).
We report a potential therapy for DMD based on the appli-
cation of 29-O-methyl antisense oligoribonucleotides (AOs) to
induce specific exon skipping of dystrophic pre-mRNA in the
mdx mouse. We have induced exon skipping as determined by
reverse transcription–PCR (RT-PCR) amplification of RNA
extracted from cultured cells after delivering AOs targeted to
splice site sequences around the mdx mutation in exon 23.
Dystrophin synthesis and correct localization to the sarcolemma
of muscle fibers in vivo was demonstrated after intramuscular
injections of the same AOs. The removal of dystrophin exon 23
does not disrupt the reading frame, so the induced mRNA can
be translated into a Becker-dystrophin-like protein. This slightly
shortened product has the potential to minimize the severity of
DMD, because some variants of dystrophin in BMD patients
correlate with a milder phenotype (17, 18). The consequences of
DMD mutations arising from genomic deletions could be re-
duced by inducing specific removal of one or more adjacent
exons to restore the reading frame. Although this type of
approach is unlikely to completely cure all cases of DMD, the
potential exists for a significant reduction in the severity of
symptoms in those patients who do not have mutations involving
crucial functional regions of the gene.
Materials and Methods
AOs. HPLC-purified AOs (Geneworks, Adelaide, Australia)
were designed complementary to the sequences available for
introns 22 and 23 (GenBank Accession nos. AF062829 and
AF062830, respectively). Their locations relative to exon 23
splice sites are indicated in Fig. 1. AO 59SS-FITC was identical
in sequence to AO 59SS-20 but was also labeled at the 59 end with
fluorescein (IDT, Coralville, IA).
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Cell Culture and Transfection. The H-2Kb-tsA58 mdx myoblasts (19)
were proliferated at 33°C under a 10% CO2y90% air atmosphere
in high-glucose DMEM supplemented with 20% fetal calf serum
and 10% horse serum, 0.5% chicken embryo extract (Life
Technologies), and 20 unitsyml g-interferon (Roche Molecular
Biochemicals). Cells were then treated with trypsin and plated
at 2 3 104 cells per well in 24-well plates coated with 50 mgyml
poly(D-lysine, Sigma) followed by 100 mgyml Matrigel (Becton
Dickinson) for differentiation and fusion at 37°C under 5% CO2
in 5% horse serum DMEM. H-2Kb-tsA58 mdx cells were trans-
fected 48 h after trypsin treatment in a final volume of 0.5 ml of
antibiotic- and serum-free Opti-MEM (Life Technologies). Each
well was treated with 1 mg (’300 nM) of appropriate AO
complexed with 2 mg of Lipofectin (Life Technologies) accord-
ing to the supplier’s instructions. After 3 h of incubation, the
transfection medium was replaced with DMEM supplemented
with 5% horse serum.
RNA Extraction and Nested RT-PCR Analysis. Cells were transfected
as duplicate wells with Lipofectin–AO complexes, incubated as
specified, and then pooled for total cellular RNA extraction with
RNAzol B (Tel-Test, Friendswood, TX) directly on the plate 72 h
after transfection. RT-PCR was carried out with 200 ng of total
RNA as the starting material for 40 cycles of amplification in the
Titan One-Tube RT-PCR system (Roche Molecular Biochemi-
cals). Briefly, forward and reverse primers amplifying from
exons 20 and 26, respectively (Ex20Fo, 59-CAGAATTCTGC-
CAATTGCTGAG-39; Ex26Ro, 59-TTCTTCAGCTTGTGT-
CATCC-39), were used at an annealing temperature of 55°C with
an extension time of 2 min at 72°C. One microliter of the
RT-PCR product was used as template in a 50-ml secondary
nested PCR with 0.5 unit of Tth Plus (Biotech, Perth, Australia)
and inner primers (Ex20Fi, 59-CCCAGTCTACCACCCTAT-
CAGAGC-39; Ex26Ri, 59-CCTGCCTTTAAGGCTTCCTT-39).
The secondary PCR was carried out for 30 cycles under cycling
conditions identical to the primary amplification. Products were
examined by electrophoresis in 3% agarose TrisyacetateyEDTA
(TAE) gels.
In Vivo Treatments. Over a 4-week period, 21-day-old C57BLy
10ScSn-mdx mice were given weekly intramuscular injections of
1 mg of AO 59SS-25 complexed with 2 mg of Lipofectin (2:1
weight ratio) prepared in saline. The right quadriceps-femoris
complex received the injection on weeks 1, 2, 3, and 4, whereas
the left received the injection on weeks 3 and 4 only. A green
histological marking dye (Wak Chemie Medical, Hamburg,
Germany) was added to the complexes to mark the injection site.
One animal underwent a parallel injection regime using only 2
mg of Lipofectin in saline. Mice were killed 1 week after the final
injection.
Sectioning and Immunohistochemical Staining. Muscles were pre-
pared for histological analysis by quenching in liquid nitrogen-
cooled isopentane. Five-micrometer sections were cut on a
Tissue-Tek II cryostat and fixed on glass slides. Immunostaining
was slightly modified from methods described previously (20).
Serial sections were sequentially blocked with normal mouse
serum, followed by 0.1% avidin solution (Sigma), then 0.01%
biotin solution (Sigma), and finally 5 mM levamisole (Sigma).
Specific mouse monoclonal antibodies directed against the C
terminus of dystrophin, DYS2 (1:30 dilution; NovoCastra, New-
castle, U.K.) and against g-sarcoglycan (1:30 dilution; Novo-
Castra) were separately labeled with a biotinylated-anti-mouse
Fab fragment (Dako) according to the supplier’s instructions.
Excess biotinylation agent was blocked with normal mouse
serum. Color was detected with alkaline phosphatase-
conjugated streptavidin (Dako) followed by Vector red fluores-
cent substrate (Vector Laboratories) according to the supplier’s
instructions. Duplicate serial sections from each treated muscle
were stained on the same slides as age-matched control sections
taken from the respective muscle of an untreated animal. All
normal untreated and AO-treated mdx immunostained sections
were photographed under the same time and exposure param-
eters to allow direct comparison. Duplicate slides were also
stained in the absence of primary antibody and did not reveal any
sarcolemmal fluorescence (data not shown).
Western Blotting. Muscle samples were homogenized in 19 vol
of protein extraction buffer [125 mM TriszHCl, pH 6.8y0.1%
SDSy2 M ureay10% (volyvol) 2-mercaptoethanoly10% (wtyvol)
glycerol], and total protein was quantitated with a Bio-Rad DC
Protein Assay Kit. Two hundred micrograms of protein from
each sample was loaded onto a 4–8% polyacrylamide gel
containing 0.2% SDS in Tris–glycine buffer. Samples were
electrophoresed overnight at 0.8 mAycm at 4°C. The fraction-
ated proteins were electroblotted onto a nitrocellulose mem-
brane at 1000 mA for 7 h. Unreacted binding sites on the
membrane were blocked with 5% (wtyvol) skim milk solution for
60 min at room temperature. Membranes were probed with
DYS2 (1:25) for 60 min followed by three washes in TBST buffer
(10 mM TriszHCl, pH 8.0y150 mM NaCly0.05% Tween 20) and
incubation with a horseradish peroxidase-conjugated secondary
Fig. 1. Sequences and relative binding sites of AOs. The sequence of exon 23 of mouse dystrophin is indicated by capitals and a shaded box, whereas the intronic
sequences neighboring the exon are indicated by lowercase and a plain box. The mdx mouse has a nonsense mutation at nucleotide 3185 causing premature
termination of translation in this exon. The sequence and orientation of all the AOs used in this study are indicated, except for AO-random (59-CCAGAUCGGA
CGACGUCAGG ACAAC-39), which was designed not to hybridize to any known sequence as validated by a BLAST database search. The fluorescein (FITC) group
of AO 59SS-FITC was attached to the 59 end of the sequence as indicated.








antibody (1:1000; Dako) for 60 min. Chemiluminescent detec-
tion of proteins was carried out with Lumi-Light Plus substrate
(Roche Molecular Biochemicals) according to the supplier’s
instructions. Membranes were then exposed to Lumi-Film
(Roche Molecular Biochemicals).
Results
AO Delivery in Vitro. We have previously reported the induction of
exon 23 skipping in cultured primary mdx myoblasts and C2C12
cells by using AO 59SS-20 (21). In that series of experiments, an
18-mer directed at the 39 splice site of intron 22 failed to induce any
exon skipping. On the basis of these results, we designed a second
generation of longer AOs (Fig. 1) and evaluated their ability to
modify exon 23 processing in immortalized H-2Kb-tsA58 mdx cells.
A f luorescein labeled oligoribonucleotide, AO 59SS-FITC,
was used to determine the optimal LipofectinyAO ratio for
nuclear uptake in cultured muscle cells. After titrating the
amount of Lipofectin against a constant amount (1 mg) of AO
59SS-FITC and comparing H-2Kb-tsA58 mdx cell survival
versus nuclear f luorescence (data not shown), the optimal
ratio was established to be 2:1 (wtywt) LipofectinyAO. No
nuclear f luorescence was observed before 3 h after transfec-
tion, while the complexes were presumably being endocytosed.
Neither was nuclear f luorescence observed when H-2Kb-tsA58
mdx cells were transfected in the presence of serum or with
equimolar amounts of uncomplexed AO 59SS-FITC (data not
shown). Lipofectin–AO complexes were able to transfect
H-2Kb-tsA58 mdx myoblast cells (1 day after plating), or fused
myotubes (8 days after plating) and induce exon skipping with
no apparent loss of efficiency. Uncomplexed AOs were unable
to consistently induce skipping in either cell state (data not
shown), suggesting that exon skipping depended on successful
delivery rather than state of differentiation. Transfections
under optimal conditions were reproducible between prepa-
rations of the immortalized H-2Kb-tsA58 mdx cells and rou-
tinely yielded transfection efficiencies of ’100% of the myo-
tubes, many of which exhibited characteristic multiple
f luorescent nuclei (Fig. 2).
AO Design. The 18-mer directed at the 39 splice site of intron 22
failed to induce exon 23 skipping (21), suggesting that this AO
may have been too short to influence splicing. Consequently, two
longer AOs were designed, a 30-mer directed at the splice
acceptor site, and a 25-mer directed at the branch point site, AO
39SS-30 and AO 39SS-BPS, respectively. Both of these AOs failed
to induce any exon skipping, either individually (Fig. 3) or when
delivered in combination (data not shown).
In marked contrast, a 25-mer, AO 59SS-25, directed at the
59 splice site of intron 23, was highly efficient at inducing exon
23 removal during pre-mRNA processing in H-2Kb-tsA58 mdx
cells. The 20-mer, AO 59SS-20, which we previously used to
induce exon 23 skipping in primary mdx myoblasts and C2C12
cells, was inconsistent in its ability to cause excision of exon 23
in H-2Kb-tsA58 mdx cells under these transfection conditions
(Fig. 3). AO 59SS-25 annealed to the same exonic region as AO
59SS-20, but it hybridized to an additional five bases into intron
23 (Fig. 1). This longer AO induced efficient and reproducible
exon skipping (Fig. 3) at a concentration of 300 nM with 2 3
104 H-2Kb-tsA58 mdx cells. Under identical transfection con-
ditions, AO 59SS-FITC was less efficient than AO 59SS-25, but
more efficient than AO 59SS-20 at causing exon 23 skipping.
Although AO 59SS-FITC has an identical sequence to AO
59SS-20 (Fig. 1), the f luorescent tag coupled to the 59 end of
the molecule would extend further into intron 23 than the
unlabeled AO, suggesting that regions further into the intron
may be more sensitive to the inf luence of these AOs on
splicing.
In addition to the removal of exon 23, other shorter RT-
PCR products were also generated after treatment with AO
59SS-25. These corresponded to an in-frame transcript arising
from the removal of exons 21–23, and a larger out-of-frame
transcript skipping exons 22–23. An additional out-of-frame
product corresponding to a transcript missing exon 21 was
observed intermittently in treated and untreated samples,
although it was seen more frequently in treated samples. These
transcripts have been observed previously (21). Specificity of
the AO action was confirmed after using a sense oligoribo-
nucleotide complementary to AO 59SS-20yAO 59SS-FITC
and a random sequence oligoribonucleotide, neither of which
was observed to induce exon skipping in dystrophin mRNA
(Fig. 3).
Dystrophin Expression in Injected mdx Muscle. Dystrophin immu-
nostaining of mdx muscle treated with AO 59SS-25 complexed
with Lipofectin revealed discontinuous sarcolemmal staining
in the vicinity of the green dye in muscle from both the 2- and
4-week injection programs (Fig. 4). There was no discernible
difference in staining intensity between the two time points.
Mdx muscle treated with uncomplexed AO 59SS-25 also
showed dystrophin expression but at a lower level (data not
shown). Regions of treated muscle where no green dye was
observed did not stain for dystrophin. Similarly, no staining
was observed in untreated muscles (triceps and tibialis
Fig. 2. Efficient nuclear uptake of liposome-complexed fluorescein-labeled
AO by H-2Kb-tsA58 mdx cells. Cultured H-2Kb-tsA58 mdx myotubes were
assessed for uptake of fluorescence after exposure to complexes of Lipofectin
and AO 59SS-FITC (2:1 ratio). Nuclear fluorescence was observed in ’100% of
the myotubes 3 h after transfection, with some pinpoint foci of fluorescence
located in the cytoplasm and at the cell surface (B). Many of the transfected
myotubes displayed multiple fluorescent nuclei (A).
Fig. 3. AO-induced exon skipping in H-2Kb-tsA58 mdx myoblasts. Total RNA
was extracted from treated and untreated H-2Kb-tsA58 mdx cells and ampli-
fied by nested RT-PCR using primers annealing to exons 20 and 26. Transfec-
tions were carried out as described in the text with the indicated AOs. The
901-bp full-length transcript was detected in all samples except the PCR
negative (-ve) control. Lane M, size markers. A shorter product of 688 bp
(arrow), corresponding to the removal of exon 23, was amplified from cell
extracts transfected with AO 59SS-FITC and AO 59SS-25.
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anterior) from treated mice, or muscle treated with Lipofectin
only.
Similar staining patterns were observed when serial sections
were stained with an antibody recognizing g-sarcoglycan, a
component of the dystrophin–glycoprotein complex (DGC)
(22). Reduced expression and localization of members of
the DGC, including g-sarcoglycan, are common features of
muscular dystrophies (23), so the detection of this protein
implies that the induced dystrophin has restored some of
the DGC.
Western blot analysis of total protein demonstrated the pres-
ence of a protein of expected size from normal C57BLy10ScSn
mouse muscle extracts and both treated mdx muscle samples,
but not untreated mdx control muscle (Fig. 5). As with the im-
munostaining results, there appeared to be little quantita-
tive difference in dystrophin levels between the 2 and 4 week
treatments. There was no discernible size difference between
normal dystrophin (427 kDa) and AO-induced dystrophin, ex-
pected to be 420 kDa, where the absence of exon 23 would
remove only 71 amino acids.
Fig. 4. Demonstration of antisense-induced dystrophin synthesis and restoration of g-sarcoglycan in C57BL mdx mouse muscle. Immunostaining of normal
C57BL mouse muscle (A) and untreated C57BL mdx muscle (B) with antibody DYS2 revealed sarcolemmal staining of dystrophin and a complete absence of the
protein, respectively. However, sarcolemmal dystrophin staining was observed in a broad spread of mdx muscle fibers 1 week after injection of Lipofectin–AO
59SS-25 (2:1 ratio) complexes into the left quadriceps-femoris complex (C). At higher magnification, dystrophin staining was revealed to be discontinuous,
reminiscent of BMD staining, in both the left (E) and right (G) legs. Phase-contrast light microscopy of the same region (F and H, respectively) shows the green
dye used to locate the site of the injection. No positive dystrophin staining was observed in an age-matched mdx control muscle when stained on the same slide
as the treated sections and photographed under identical conditions (D). Serial sections of treated muscle stained with antibodies against g-sarcoglycan revealed
restoration of g-sarcoglycan to the sarcolemma of muscle fibers that also stained positively for dystrophin (J). No staining was observed in the same muscle of
an age-matched mdx control section also stained for g-sarcoglycan (I).









Kole and colleagues (24) pioneered the use of AOs to influence
splicing by blocking a cryptic splice site in mutated b-globin
pre-mRNAs to restore normal processing. We have reinter-
preted their approach by blocking normal splice sites in a
dystrophic pre-mRNA to induce abnormal splicing to remove an
exon carrying a nonsense mutation.
AOs were designed complementary to elements involved in the
splicing of dystrophin exon 23 in the mdx mouse. The ability of these
AOs to induce efficient exclusion of exon 23 from processed
dystrophin mRNA in the immortalized H-2Kb-tsA58 mdx cell line
was assayed by RT-PCR. Injection of Lipofectin–AO complexes
into the hind limb muscles of mdx mice, followed by RT-PCR and
protein analysis, demonstrated specific exon 23 skipping and sub-
sequent synthesis and correct localization of dystrophin and resto-
ration of at least one component of the dystrophin–glycoprotein
complex at the muscle fiber periphery. This demonstrates the
potential of this alternative genetic therapy for DMD by using
antisense chemistry to redirect splicing of mutated dystrophin
pre-mRNA, allowing synthesis of a shorter but theoretically semi-
functional, or Becker-dystrophin-like protein in dystrophic muscle.
Delivery of the AOs and translocation to the nucleus was
shown not to be a limiting factor in vitro, as virtually the whole
population of cultured cells displayed fluorescent nuclei after
transfection with a fluorescein-labeled AO complexed with
Lipofectin. Although delivery of naked plasmid is possible in
whole muscle (25), and endocytotic uptake of naked AOs has
been demonstrated in a variety of cell types in vitro (26, 27), we
failed to observe fluorescence or exon skipping when H-2Kb-
tsA58 mdx cells were treated with uncomplexed AOs.
The efficiency of inducing exon skipping in the immortalized
H-2Kb-tsA58 mdx cells seemed more dependent on the target site
rather than length of the AO, where exon 23 removal was
enhanced by using a longer oligoribonucleotide directed at the
intron 23 59 splice site. However, AO length alone will not
influence exon skipping if the target site is not sensitive to
blocking or is inaccessible because of pre-mRNA secondary or
tertiary structure or competition with splicing factors. For
example, two AOs directed at splicing motifs at the end of intron
22, AO 39SS-30 and AO 39SS-BPS (a 30-mer and a 25-mer,
respectively), both failed to induce exon skipping, consistent with
our previously reported observations in experiments using an
18-mer AO to this region (21).
There are numerous examples of 39 and 59 splice site
mutations leading to skipping of only the adjacent exon in the
dystrophin gene (28–30). Inducing efficient skipping at the 59
splice site appeared to be dependent on blocking intronic
motifs, rather than only those at the exon–intron junction. The
first two bases of the intron are highly conserved and generally
considered to be essential for correct splicing (31). Only
minimal and sporadic skipping was induced in H-2Kb-tsA58
mdx cells transfected with AO 59SS-20, whereas AO 59SS-25
was consistently more efficient at removing exon 23 from
dystrophin pre-mRNA transcripts. Furthermore, the f luores-
cein tag attached to the 59 end of AO 59SS-FITC conferred on
it the ability to redirect splicing with greater efficiency than
AO 59SS-20, even though the sequences of the two are
identical. No splicing elements are known to exist in this
intronic region, although consensus sequences crucial to splic-
ing are short and not well conserved (31).
Preliminary in vivo experiments using lower doses of AO
injected intramuscularly over 1 to 2 weeks resulted in low but
detectable levels of correctly localized dystrophin in some
treated mice (data not shown). In the experiments described
here a 10-fold higher dose of AO delivered over 2 to 4 weeks
resulted in substantial levels of dystrophin. This result was
obtained from direct intramuscular delivery 5 weeks after initial
treatment without immunosuppression of the animals. More
detailed analysis of AO dosage and delivery is needed, along
with studies of dystrophin expression and long-term persistence.
Immunostaining for dystrophin demonstrated discontinuous
fluorescence around the sarcolemma of numerous successfully
treated muscle fibers (Fig. 4C). This pattern of staining, ob-
served in the majority of treated muscles, was reminiscent of that
typically observed in sections from BMD patients (32). The
discontinuous peripheral staining could be used to distinguish
treated fibers from the rare naturally occurring revertants, which
usually display continuous sarcolemmal staining. Revertant fi-
bers in the mdx mouse typically occur as single fibers or small
clusters undetectable by Western blotting (10). Some cytoplas-
mic staining of dystrophin was also present in the AO-treated
fibers, and this is not typically seen in revertants, a further point
of differentiation between AO-treated and natural dystrophin-
positive fibers. Cytoplasmic staining has been observed in mdx
mouse muscle transfected with dystrophin constructs under the
control of Rous sarcoma virus promoters (35). Overexpression
of dystrophin has not been associated with abnormalities in
muscle fiber architecture or toxicity. The number of fibers visible
in the treated section, the discontinuous peripheral and cyto-
plasmic staining, and the presence of a near-full-length protein
in the Western blot confirm that dystrophin has been induced in
the mdx mouse after AO therapy. Dystrophin immunostaining
was not detected in the mdx muscle that was injected with
liposome only, indicating that the induced dystrophin synthesis
did not arise from either the delivery agent or repeated physical
damage during the multiple injections (data not shown).
Staining of serial sections also demonstrated the partial
restoration of g-sarcoglycan at the periphery of those fibers that
also stained for dystrophin. This observation suggested that the
induced dystrophin was capable of restoring the complex of
membrane glycoproteins, and presumably some function, to the
AO-treated muscle.
The Western blot clearly demonstrated a single protein with
an electrophoretic mobility approximately that of full-length
normal dystrophin in muscle treated for either 2 or 4 weeks. This
induced dystrophin isoform could not have arisen from sampling
unusually large clusters of revertant fibers. We have shown that
revertant fibers result from a spectrum of dystrophin isoforms,
the most common of which arise from skipping of 20 or more
exons (11). The lack of size difference observed between normal
and induced dystrophin on the Western blot was expected,
because removal of only exon 23, which codes for 71 amino acids,
would not significantly alter the fractionation of such a large
(427-kDa) protein through a polyacrylamide gel. Detailed in vivo
RT-PCR studies have not yet been undertaken, as the emphasis
has been placed on protein studies. Nevertheless, dystrophin
Fig. 5. Synthesis of near full-length dystrophin in muscle of mdx mice
treated with Lipofectin–AO 59SS-25 complexes. Western blotting of total
protein extracted from the quadriceps-femoris complex of mice treated
with Lipofectin–AO 59SS-25 (2:1 ratio) complexes revealed synthesis of
near-full-length dystrophin compared with dystrophin extracted from nor-
mal C57BL muscle. No dystrophin protein was detected in muscle samples
of untreated mdx mice.
46 u www.pnas.org Mann et al.
transcripts skipping only exon 23 have been detected, and have
been confirmed by direct DNA sequencing, 72 h after Lipofec-
tin–AO delivery into mdx muscle (data not shown).
Induction and localization of a Becker-dystrophin-like pro-
tein in mdx muscle demonstrates the feasibility of an AO-based
approach for treating DMD. As well as representing another
therapy for a disease where numerous experimental treat-
ments have met with disappointment (8, 36), this antisense-
based approach has several potential advantages over those
gene or cell replacement therapies. First, all of the tissue-
specific and developmental control elements of dystrophin
expression will remain intact (35, 36); liposomes will only have
to deliver small payloads, unlike recombinant viral vectors;
repeated delivery should be possible because the host should
not develop immune responses against transduced cells as
happens against virus-based therapies (37); and the costs of
AO production should be much lower than those for preparing
recombinant viruses. The major disadvantage of this particular
AO therapy is that it will not be applicable to all dystrophin
mutations, such as very large deletions, or mutations that
disrupt or necessitate exclusion of crucial functional domains.
Detailed characterization of the dystrophin mutations in BMD
patients, especially those with a mild phenotype, will provide
a useful guide as to which regions of dystrophin may be
amenable to removal from the final product, and to the extent
of phenotypic rescue that may be achievable. For example, the
patient from whom the dystrophin ‘‘minigene’’ was derived had
a mild phenotype despite the loss of 46% of the rod domain
(38), whereas another patient with a smaller deletion of exons
3 to 9 was a competitive badminton player until his early 60s
and was not diagnosed until his mid-60s (18). By using
dystrophin transcripts from such patients as templates, the
carefully orchestrated targeting of multiple exons could induce
a protein capable of minimizing the severity of DMD. Finally,
like all gene therapy protocols, the universal problem of
delivery needs to be continually reassessed (8). Systemic
delivery rather than intramuscular injection will undoubtedly
be required to distribute the AOs if any significant clinical
efficacy is to be obtained. Further experiments are necessary
to address this problem of delivery, as well as to assess sites
more sensitive to AO-targeted exon removal in other regions
of the dystrophin gene.
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